Skip to main
AGL
AGL logo

Agilon Health (AGL) Stock Forecast & Price Target

Agilon Health (AGL) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 18%
Buy 32%
Hold 41%
Sell 9%
Strong Sell 0%

Bulls say

Agilon Health Inc. demonstrated strong financial growth in the fourth quarter, with total revenue increasing by 44.2% year-over-year, exceeding estimates by 0.2%. The company's membership in Medicare Advantage (MA) grew by 36% year-over-year, reaching 527,000 members, which supports revenue growth potential and reflects strong market demand. Additionally, the improved medical margin, despite missing estimates, hints at enhanced operational efficiency as the company gains access to timely hospital census data, setting a positive trajectory for future financial performance.

Bears say

Agilon Health's stock outlook is impacted negatively by its visibility issues, particularly in the second half of the year, which have led to unforeseen financial results, including an adjusted EBITDA of $(84.0) million in 4Q24, falling short of both consensus estimates and prior guidance. The company reported significantly lower medical margins, with actual figures of $0.6 million compared to expectations of $19.8 million, raising concerns about the sustainability of its revenue sources. Additionally, guidance for ACO REACH patients shows a decline of 20.5% to 12.9% quarter-over-quarter, indicating potential challenges in growth and profitability moving forward.

Agilon Health (AGL) has been analyzed by 22 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 32% recommend Buy, 41% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agilon Health (AGL) Forecast

Analysts have given Agilon Health (AGL) a Buy based on their latest research and market trends.

According to 22 analysts, Agilon Health (AGL) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agilon Health (AGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.